USING TERLIPRESSIN AIMED TO REDUCE BLOOD LOSS IN CESAREAN SECTION
https://doi.org/10.21292/2078-5658-2018-15-6-20-27
Abstract
The objective of the study: to assess the impact of the agonist of vasopressin receptor V-1 (terlipressin) in the operative delivery of obstetric patients with a high risk of hemorrhage during cesarean section.
Subjects and methods. 60 women were examined, all of them had planned cesarean section; the median age made 32.7 years and gestation time made 38 weeks. Group 1 (n =30) included patients who underwent surgery without terlipressin; Group 2 (n =30) included women who had 0.4 mg of terlipressin intra-operatively introduced endometrially (into the place of the uterus incision) immediately after omphalotomy. The volume of the blood loss was measured intra-operativelly. The arterial tension and hemodynamic rates were assessed during the surgery and in 24 hours after it in the morning.
Results. It was found out that there was a statistically significant difference in the volume of intra-operative blood loss and need for blood transfusion. Using terlipressin resulted in the reduction of blood loss by 37–50% which was due to its pharmacological effects, i.e. vasoconstrictive and antihemorrhagic ones.
Conclusions. Using terlipressin within comprehensive intensive care during cesarean section in the patient facing the high risk of hemorrhage allows reducing the intra-operative blood loss to a significant extent and reducing transfusion of donor blood components.
About the Authors
Yu. S. Аleksandrovich
St. Petersburg State Pediatric Medical University
Russian Federation
Russian Federation
Yury S. Aleksandrovich - Doctor of Medical Sciences, Professor of Anesthesiology, Intensive Care and Emergency Pediatrics Department within Professional Development Unit
2, Litovskaya St., St. Petersburg, 194100
A. V. Rostovtsev
Voronezh Regional Clinical Hospital no. 1, Perinatal Center
Russian Federation
Russian Federation
Andrey V. Rostovtsev - Head of Anesthesiology and Intensive Care Department no.5, Chief Visiting Anesthesiologist and Emergency Physician Specializing in Obstetrics and Gynecology in Voronezh Region
151, Moskovskiy Ave., Voronezh, 394066
E. S. Kononova
Voronezh Regional Clinical Hospital no. 1, Perinatal Center
Russian Federation
Russian Federation
Elena S. Kononova - Doctor of Anesthesiology and Intensive Care Department no. 5
151, Moskovskiy Ave., Voronezh, 394066
O. V. Ryazanova
St. Petersburg State Pediatric Medical University
Russian Federation
Russian Federation
Oksana V. Ryazanova - Head of Intensive Care Department
2, Litovskaya St., St. Petersburg, 194100
T. I. Аkimenko
Public Clinic Named after Peter the Great
Russian Federation
Russian Federation
Tatiana I. Akimenko - Anesthesiologist and Emergency Physician
47, Piskarevsky Ave., St. Petersburg, 195067
References
1. Barinov V.V., Zhordania K.I., Payanidi Yu.G. et al. Feasibility of using terlipressin (Remestyp) in the management of hemorrhage in surgical treatment in gynecologic oncology (ovarian cancer and cervical cancer). Onkoginekologiya, 2014, no. 1, pp. 73-77. (In Russ.)
2. Bryunnler T., Mandraka F., Langgartner Yu. Terlipressin: clinical use, rational dosing, comparison of efficacy of various dosing regimens. Clinic of University of Regensburg, Germany. Intensivmedzin und Notfallmedizin,2005, vol. 42, no. 5. Available: https://docviewer.yandex.ru/view
3. Bondar T.P., Muratova А.Yu., Shatalova G.Yu. Consistent patterns of hemostasis in the system of Mother – Child in case of noncomplicated pregnancy and trombophilia. Vestn. Stavropolskogo Gosudarstvennogo Universiteta, 2010, no. 4, pp. 187-195. (In Russ.)
4. Dron A.N. Physiological changes in hemostasis in different life time periods. Meditsinskaya Nauka i Obrazovanie Urala,2012, vol. 13, no. 2-3, pp. 123-127. (In Russ.)
5. Eralina S.N., Ismailov E.L. Intensivnaya terapiya v akusherstve. [Intensive care in obstetrics]. Monografiya. Almaty, 2017, 264 p.
6. Kaprin А.D., Starinskiy V.V., Petrova G.V. Zlokachestvennye novoobrazovaniya v Rossii v 2015 g.(zabolevaemost i smertnost').[Malicious tumors in Russia in 2015. (Incidence and mortality)]. Р. A. Hertsen Moscow Oncology Research Institute – Branch of the National Medical Research Radiological Center of the Ministry of Health of the Russian Federation, Moscow, 2017, 250 p.
7. Kiryuschenkov P.A. The physiology of hemostasis and its particular features in non-complicated pregnancy. Effektivnaya Farmakoterapiya,2010, no. 4, pp. 18-22. (In Russ.)
8. Klimenko Yu. New opportunities of medicamentous hemostasis in the obstetric and gynecological practice. Zdorovya Ukraini, 2009, no. 24 (1), pp. 55.
9. Krasnopolskaya K.V., Аshkharua T.А. Use of selective stimulators of dophamine D2 receptors for the prevention of ovarian hyperstimulation syndrome (literature review). Probl. Reprod., 2011, no. 3, pp. 63-68. (In Russ.)
10. Marshalov D.V., Salov I.А., Shifman E.M. et al. The role of intra-abdominal hypertension in the development and outcomes of ovarian hyperstimulation syndrome. Tolyat. Med. Konsil., 2013, vol. 3–4, pp. 57-66. (In Russ.)
11. Pavlovskaya Yu.M., Vorobiova N.А. Fibrinogen and factor XIII in pregnancy. Vestnik Severnogo (Аrkticheskogo) Federalnogo Universiteta. Seriya: Mediko-Biologicheskie Nauki,2015, no. 1, pp. 68-75. (In Russ.)
12. Polikarpova T.S., Mazurchik N.V., Ogurtsov P.P. et al. Hepatorenal syndrome: diagnostic criteria, approaches to therapy and opportunities of using terlipressin. Klin. Farmakol. i Terapiya,2009, vol. 18, no. 4, pp. 23-31. (In Russ.)
13. Pylaeva N.Yu., Jovbak V.M., Zhdanyuk L.А. et al. The blood saving effect of the agonist of vasopressin receptor V-1 in the surgery of main arteries of lower extremities. Materialy XXX Mezhdunarodnoy Konferentsii Novye napravleniya v lechenii sosudistykh bolnykh, Sochi, 25–27 iyunya 2015.[Abst. Book of the XXXthe International Conference on New Trends in the Management of Patients with Vascular Disorders, Sochi, June 25-27, 2015]. pp. 506-507. (In Russ.)
14. Ryazanova O.V., Аleksandrovich Yu.S., Shifman E.M. et al. Current aspects of uterine bleeding management in placental presentation. Pediatr, 2016, vol. 7, no. 3, pp. 117-127. (In Russ.)
15. Sapicheva Yu.Yu., Kassil V.L. Аnalizy glazami reanimatologa.[Laboratory tests from the point of view of the emergency physician]. A.M. Ovezov, eds., 3rd ed., suppl. and amend., Moscow, MEDpress-inform Publ., 2016, 224 p.
16. Khvatov V.B., Borovkova N.V., Valetova V.V. et al. Specific features and monitoring of transfusive hemocorrection in the emergency surgery. Аlmanakh Klin. Meditsiny,2009, no. 20, pp. 16-20. (In Russ.)
17. Abdelaleem A.A., Abbas A.M., Thabet A.L. et al. The effect of initiating intravenous oxytocin infusion before uterine incision on the blood loss during elective cesarean section: a randomized clinical trial.J. Matern. Fetal. Neonatal. Med., May, 2018, 9:1-6. doi: +7(1080)1476705820181471461.
18. Ventskivska I.B., Bila V.V., Leush S. St. et al. The use of remestyp in order to reduce the volume of blood loss in placental presentation. Zdorovya Ukraini, 2010, vol. 3 (14), pp. 61.
19. Bloch E.M., Ingram C., Hull J. et al. Risk factors for peripartum blood transfusion in South Africa: a case-control study. South Africa Program of the NHLBI Recipient Epidemiology and Donor Evaluation Study-III (REDS-III). Transfusion, 2018, doi: 10.1111/trf.14772.
20. Dimitrov A., Nikolov A., Krŭsteva K. et al. The use of the vasoconstrictor hemostatic Remestyp in surgical obstetrics. Akush Ginekol (Sofiia), 1999, vol. 38, no. 3, pp. 58-60.
21. Erdogan S., Bosnak M. Using terlipressin in a pediatric patient with septic shock resistant to catecholamines. North Clin. Istanb., 2017, vol. 4, no. 3, pp. 283-287.
22. Geller S.E., Koch A.R., Garland C.E. et al. A global view of severe maternal morbidity: Moving beyond maternal mortality. Reprod Health, 2018, vol. 22, no. 15, suppl. 1, pp. 98. doi: 10.1186/s12978-018-0527-2.
23. Hoskins I., Berg R. Correlation of blood lactate levels as a predictor for blood transfusion in postpartum hemorrhage. Obstetrics &Gynecology, 2017, vol. 129, no. 5, P. 23S. doi: 10.1097/01.AOG.0000514385.27179.e7.
24. Katz D., Hamburger J., Batt D. et al. Point-of-care fibrinogen testing in pregnancy. Anesth. Analg., 2018, vol. 23. doi: 10.1213/ANE.0000000000003301.
25. Peng Q., Zhang W., Liu Y. Clinical application of stage operation in patients with placenta accreta after previous caesarean section. Medicine (Baltimore),2018, vol. 97, no. 22, pp. e10842. doi: 10.1097/MD.0000000000010842.
26. O'Brien K.L., Shainker S.A., Lockhart E.L. Transfusion Management of Obstetric Hemorrhage. Transfus. Med. Rev., 2018, vol. 32, no. 4, pp. 249–255. doi: 10.1016/j.tmrv.2018.05.003.
27. Rafiei M., Saei Ghare M., Akbari M. et al. Prevalence, causes, and complications of cesarean delivery in Iran: A systematic review and meta-analysis. Int. J. Reprod. Biomed. (Yazd), 2018, vol. 16, no. 4, pp. 221-234.
Review
For citations:
Аleksandrovich Yu.S., Rostovtsev A.V., Kononova E.S., Ryazanova O.V., Аkimenko T.I. USING TERLIPRESSIN AIMED TO REDUCE BLOOD LOSS IN CESAREAN SECTION. Messenger of ANESTHESIOLOGY AND RESUSCITATION. 2018;15(6):20-27. (In Russ.) https://doi.org/10.21292/2078-5658-2018-15-6-20-27
Email this article 